Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors

PURPOSE: Napabucasin is a cancer stemness inhibitor that targets a number of oncogenic pathways, including signal transducer and activator of transcription 3 (STAT3). Phase 1/2 studies suggest tolerability and anti-tumor activity in various types of cancer; a Phase 3 study of napabucasin plus standa...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Chemother Pharmacol
Päätekijät: Kawazoe, Akihito, Kuboki, Yasutoshi, Bando, Hideaki, Fukuoka, Shota, Kojima, Takashi, Naito, Yoichi, Iino, Shuichi, Yodo, Yasuhide, Doi, Toshihiko, Shitara, Kohei, Yoshino, Takayuki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Berlin Heidelberg 2020
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188713/
https://ncbi.nlm.nih.gov/pubmed/32236642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04059-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia